Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.

doi:10.1158/1078-0432.CCR-14-0341

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2014

Zimmer Lisa, Barlesi Fabrice, Martinez-Garcia Maria, Dieras Veronique, Schellens Jan H M, Spano Jean-Philippe, Middleton Mark R, Calvo Emiliano, Paz-Ares Luiz, Larkin James, Pacey Simon, Venturi Miro, Kraeber-Bodéré Françoise, Tessier Jean J L, Eberhardt Wilfried Ernst Erich, Paques Michel, Guarin Ernesto, Meresse Valerie, Soria Jean-Charles

Abstract excerpt

PURPOSE: This phase I expansion study assessed safety, pharmacodynamic effects, and antitumor activity of RO4987655, a pure MEK inhibitor, in selected patients with advanced solid tumor. EXPERIMENTAL DESIGN: We undertook a multicenter phase I two-part study (dose escalation and cohort expansion). Here, we present the part 2 expansion that included melanoma, non-small cell lung cancer (NSCLC), and colorectal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Benzamides

Share to Class I Phosphatidylinositol 3-Kinases

Share to MAP Kinase Kinase Kinases

Share to Oxazines

Share to Patient Selection

Share to Phosphatidylinositol 3-Kinases

Share to Tissue Distribution

Source

Open in PubMed

Identifiers

PMID: 24947927
DOI: 10.1158/1078-0432.CCR-14-0341

Genes

BRAF
KRAS
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.PMID 24947927Read ↗

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.Semantic proximity Read ↗

BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy.Semantic proximity Read ↗

First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations.Semantic proximity Read ↗

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1).Semantic proximity Read ↗

First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.Semantic proximity Read ↗

Clinical Development of BRAF plus MEK Inhibitor Combinations.Semantic proximity Read ↗

Design and biological characterization of a series of dual mechanism ERK1/2 inhibitors with a Triazolopyridinone core.Semantic proximity Read ↗

Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma CancersSemantic proximity Read ↗

BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series.Semantic proximity Read ↗

Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.Semantic proximity Read ↗

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.Semantic proximity Read ↗

Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.